ReviewJournal of controlled release : official journal of the Controlled Release Society2021
Nano-engineered tools in the diagnosis, therapeutics, prevention, and mitigation of SARS-CoV-2.
Review in Journal of controlled release : official journal of the Controlled Release Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Stimuli-Responsive Polyethylenimine Derivatives as Carriers for siRNA Delivery: Current Solutions and Future Perspectives.ACS omega · 2026Review
- Development of Receptor-Integrated Magnetically Labeled Liposomes for Investigating SARS-CoV-2 Fusion Interactions.Analytical chemistry · 2025Article
- The role of RNA structural motifs in RNA-lipid raft interaction.Scientific reports · 2025Article
- Opportunities and Challenges for Inhalable Nanomedicine Formulations in Respiratory Diseases: A Review.International journal of nanomedicine · 2024Review
- Utilizing nanozymes for combating COVID-19: advancements in diagnostics, treatments, and preventative measures.Journal of nanobiotechnology · 2023Review
- Updates on the Biofunctionalization of Gold Nanoparticles for the Rapid and Sensitive Multiplatform Diagnosis of SARS-CoV-2 Virus and Its Proteins: From Computational Models to Validation in Human Samples.International journal of molecular sciences · 2023Review
- New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention.Materials today. Chemistry · 2023Review
- Nanoparticles: Taking a Unique Position in Medicine.Nanomaterials (Basel, Switzerland) · 2023Review
- Recent advances in point of care testing for COVID-19 detection.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Single-step green synthesis of gold conjugated polyphenol nanoparticle using extracts of Saudi's myrrh: Their characterization, molecular docking and essential biological applications.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Article
- Article
- COVID-19 inflammation and implications in drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting.Nano today · 2022Article
- Diagnostic assay and technology advancement for detecting SARS-CoV-2 infections causing the COVID-19 pandemic.Analytical and bioanalytical chemistry · 2022Review
- Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment.Nanomaterials (Basel, Switzerland) · 2022Review
- Characterization of rabbit polyclonal antibody against camel recombinant nanobodies.Open life sciences · 2022Article
- Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients.Journal of drug delivery science and technology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent outbreak of SARS-CoV-2 has forever altered mankind resulting in the COVID-19 pandemic. This respiratory virus further manifests into vital organ damage, resulting in severe post COVID-19 complications. Nanotechnology has been moonlighting in the scientific community to combat several severe diseases. This review highlights the triune of the nano-toolbox in the areas of diagnostics, therapeutics, prevention, and mitigation of SARS-CoV-2. Nanogold test kits have already been on the frontline of rapid detection. Breath tests, magnetic nanoparticle-based nucleic acid detectors, and the use of Raman Spectroscopy present myriads of possibilities in developing point of care biosensors, which will ensure sensitive, affordable, and accessiblemass surveillance. Most of the therapeutics are trying to focus on blocking the viral entry into the cell and fighting with cytokine storm, using nano-enabled drug delivery platforms. Nanobodies and mRNA nanotechnology with lipid nanoparticles (LNPs) as vaccines against S and N protein have regained importance. All the vaccines coming with promising phase 3 clinical trials have used nano-delivery systems for delivery of vaccine-cargo, which are currently administered widely in many countries. The use of chemically diverse metal, carbon and polymeric nanoparticles, nanocages and nanobubbles demonstrate opportunities to develop anti-viral nanomedicine. In order to prevent and mitigate the viral spread, high-performance charged nanofiber filters, spray coating of nanomaterials on surfaces, novel materials for PPE kits and facemasks have been developed that accomplish over 90% capture of airborne SARS-CoV-2. Nano polymer-based disinfectants are being tested to make smart-transport for human activities. Despite the promises of this toolbox, challenges in terms of reproducibility, specificity, efficacy and emergence of new SARS-CoV-2 variants are yet to overcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.